Publications by authors named "David A Angulo"

Claim this Profile
A
A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis.
Oluwatosin Goje, Nkechi E Azie, David A Angulo, Ryan Sobel, Paul Nyirjesy

Am J Obstet Gynecol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.
David A Angulo, Barbara Alexander, Riina Rautemaa-Richardson, Ana Alastruey-Izquierdo, Martin Hoenigl

J Fungi (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.
Paul Nyirjesy, Jane R Schwebke, David A Angulo, Itzel A Harriott, Nkechi E Azie

Clin Infect Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Jane R Schwebke, Ryan Sobel, Janet K Gersten, Steven A Sussman, Samuel N Lederman, David A Angulo

Clin Infect Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis